Drug Search Results
Using advanced filters...
Advanced Search [+]

Trevogrumab

Alternative Names: trevogrumab, regn1033, sar391786
Clinical Status: Active
Latest Update: 2025-06-02
Latest Update Note: News Article

Product Description

Mechanisms of Action: GDF8 Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous,Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Trevogrumab

Countries in Clinic: Puerto Rico, United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

  • Clinical Outcomes Reported - Regeneron presented P2 Obesity results on 2025-06-02 for Trevogrumab
  • Clinical Outcomes Expected - Regeneron announced they will present P2 Obesity results in 2H25 for Trevogrumab

Highest Development Phases

Phase 2: Obesity

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

COURAGE

P2

Recruiting

Obesity

2026-05-27

14%

2025-05-13